



## **Combined Ordinary and Extraordinary General Meeting on June 26<sup>th</sup> 2013**

### **Preparatory documents**

**Paris, June 5<sup>th</sup> 2013** – BioAlliance Pharma's shareholders are invited to attend the Combined Ordinary and Extraordinary General Meeting to be held at 4.30 pm on June 26<sup>th</sup> 2013 at the company's head office (49 Boulevard du Général Martial Valin, F-75015 Paris, France).

The official notice of the Meeting has been published in the French Republic's Bulletin des Annonces Légales Obligatoires ("Bulletin of Mandatory Legal Announcements") dated May 20, 2013 and contains the agenda, the draft resolutions and information on attendance and voting procedures. It can be viewed on the company's web site at:

<http://www.bioalliancepharma.com/eng/Investisseurs/Shareholders-Meetings>

Notice of the meeting will also be published in an official journal of legal announcements on June 7, 2013.

Documents related to the meeting are available to shareholders, under the conditions set out in the current legislation, and are posted on the company's website at [www.bioalliancepharma.com](http://www.bioalliancepharma.com).

Shareholders may, in accordance with Articles R.225-88 and R.225-89 of the French Commercial Code, consult the afore-mentioned documents (together with the information specified in Articles R.225-81 and R.225-83 of the said Code) at the company's head office or request supply of the said documents and information by post/mail to a duly indicated postal/ mailing or electronic address by writing to BioAlliance Pharma (Direction Financière – 49 boulevard du Général Martial Valin, F-75015 Paris, France), faxing to +33 1 45 58 08 81 or sending an e-mail to [ag2013@bioalliancepharma.com](mailto:ag2013@bioalliancepharma.com).

#### **About BioAlliance Pharma**

A company dedicated to specialty and orphan products in the treatment of cancers and supportive care, with an approach focused on drug resistance. BioAlliance Pharma designs and develops innovative medicines mainly intended for hospital use and drugs in rare or orphan diseases. Created in 1997 and listed on the Euronext stock exchange in Paris in 2005, the company has ambitions to become a key player in these areas by linking innovation to patient needs. It possesses the key skills to identify, develop and register drugs in Europe and the United States.

For more information, visit the BioAlliance Pharma website at [www.bioalliancepharma.com](http://www.bioalliancepharma.com)

BioAlliance Pharma has developed a portfolio of advanced products:

**Specialty products:**

Loramyc<sup>®</sup>/Oravig<sup>®</sup> (Oropharyngeal candidiasis in immune compromised patients): Approved in 26 countries (Europe, USA, Korea), marketed in Europe and the United States.

Sitavig<sup>®</sup> (Herpes labialis): Registered in the U.S. and in 8 European countries, undergoing process in other European countries.

Fentanyl Lauriad<sup>®</sup> (chronic pain in cancer patients): Positive preliminary clinical Phase I results

**Orphan Oncology products**

Livatag<sup>®</sup> /doxorubicine Transdrug<sup>™</sup> (Hepatocellular carcinoma): Phase III

Validive<sup>®</sup> / clonidine Lauriad<sup>®</sup> (Mucositis post-chemotherapy and radiotherapy in head and neck cancer): Phase II  
Biotherapy AMEP<sup>®</sup> (Invasive metastatic melanoma): Phase I

***BioAlliance Pharma SA***

Judith Greciet, CEO

Tel: +33 1 45 58 76 00

judith.greciet@bioalliancepharma.com

Nicolas Fellmann, CFO

Tel: +33 1 45 58 71 00

nicolas.fellmann@bioalliancepharma.com

***ALIZE RP***

Caroline Carmagnol

Tel: +33 6 64 18 99 59

caroline@alizerp.com

Christian Berg

Tel: +33 1 42 68 86 41

christian@alizerp.com